Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2024) 99 EP191 | DOI: 10.1530/endoabs.99.EP191

1Department of Endocrinology, Centre of Postgraduate Medical Education, Warsaw, Poland; 2EndoLab Laboratory, Centre of Postgraduate Medical Education, Warsaw, Poland; 3Department of Endocrinology, Metabolism and Internal Medicine, Poznań University of Medical Sciences, Poznań, Poland; 4Department of Internal Medicine and Endocrinology, Medical University of Warsaw, Warsaw, Poland; 5Endocrinology & Nutrition Department, Hospital Universitario Ramón y Cajal & Instituto de Investigación Biomédica Ramón y Cajal (IRYCIS), Madrid, Spain; 6University of Alcalá, Madrid, Spain; 7Department of Endocrinology, Karolinska University Hospital, Stockholm, Sweden; 8Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden


Introduction: Adrenal incidentalomas are tumors incidentally discovered on imaging tests. Regarding functionality, although 75% of adrenal incidentalomas are non-functioning cortical adenomas (NFAA), there is a subset of adrenal incidentalomas associated with important clinical consequences: adrenocortical cancer (ACC), pheochromocytoma (PHEO, together with paraganglioma (PGL) referred as PPGL), primary aldosteronism (PA), mild-autonomous cortisol secretion (MACS) and Cushing syndrome (CS). The granin family consists of numerous proteins and derived peptides. The aim of this project was to evaluate the clinical usefulness of various proteins/peptides from the granin family in the diagnostics of patients with adrenal incidentalomas and PGLs.

Materials and methods: 80 patients with various adrenal tumors (PHEO, PA, ACC, MACS, CS, NFAA) and PGL were enrolled in the study. Plasma/serum concentrations of selected proteins/peptides were determined in all patients: Chromogranin A and derived peptides: Pancreastatin, Serpinin, WE-14, Catestatin, Vasostatin-2, and Chromogranin B, Secretogranin II and Secretoneurin. The concentration of the tested proteins and peptides in serum/plasma were determined by the ELISA/EIA method.

Results: The following results of tested biomarkers differentiating individual syndromes (PHEO, PGL, PA, ACC, MACS, CS) against patients with NFAA were obtained: PHEO vs NFAA: CgA (P=0.005), Vasostatin-2 (P=0.019), Secretoneurin (P=0.002), and SgII (P=0.001). PA vs NFAA: Pancreastatin (P=0.039). PGL vs NFAA: Secretoneurin (P=0.021), and SgII (P=0.002). ACC vs NFAA: Serpinin (P=0.044). CS vs NFAA: Serpinin (P=0.011), Pancreastatin (P=0.045), Secretoneurin (P=0.039), and SgII (P<0.001). MACS vs NFAA: SgII (P=0.011). Usefulness of the biomarkers tested in differentiating between the two groups of patients with hypercortisolemia, was not demonstrated.

Conclusions: The obtained results showed different usefulness of the tested proteins and peptides from granin family: CgA (PPGLs), Secretoneurin (PPGLs, CS, PA), SgII (PPGLs, CS), Pancreastatin (PA, CS), Vasostatin-2 (PPGLs) and Serpinin (ACC).

Volume 99

26th European Congress of Endocrinology

Stockholm, Sweden
11 May 2024 - 14 May 2024

European Society of Endocrinology 

Browse other volumes

Article tools

My recent searches

Pivonello Rosario (<1 min ago)
Nadia Charfi (<1 min ago)
Lawton Phillip (<1 min ago)
Sara (<1 min ago)
Nabila (<1 min ago)